Worldwide Urticaria Drugs Market Insights: Industry Size, Growth Analysis and Forecast
Report ID : 1374597 | Published : May 2025 | Study Period : 2023-2033 | Format : PDF + Excel
The market size of the Urticaria Drugs Market is categorized based on Drug Type (Antihistamines, Corticosteroids, Biologics, Immunosuppressants, Others) and Route of Administration (Oral, Injectable, Topical) and End User (Hospitals, Clinics, Homecare Settings, Pharmacies) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).
In 2023, the Urticaria Drugs Market size was $4.5 billion and is projected to grow to $8.2 billion by 2033, registering a CAGR of 6.5% from 2024 to 2033. This report includes multiple segments and provides an analysis of key trends and factors playing a substantial role in the market.
The Urticaria Drugs Market is emerging as one of the most dynamic pharmaceutical sectors worldwide due to the increasing cases of chronic urticaria across the globe. Urticaria or hives are defined as the itchy rashes that appear on the skin suddenly and can be very discomforting for the patients. As more and more people become aware of the condition, there is a greater need for treatment and as a result, more and more innovative drugs are being developed and approved catering towards the different kinds of urticaria.
Market players are focusing on the formulation of advanced therapeutic solutions for acute and chronic forms of the condition, including antihistamines, corticosteroids, and monoclonal antibodies. There are increasing new entrants in the market which indicates the widening pipeline of urticaria drugs which is also aligned with the latest trends in personalized medicine. This improvement in treatment methods leads to better results for the patients and at the same time, creates a market for more competitive R&D activities.
With the ongoing expansion of Urticaria Drugs Market, it presents various competing avenues for pharmaceutical firms, healthcare practitioners, and investors to explore. Stakeholders can comprehend the complexities governing the changes in the market, its trends, changes in legislation, and the set preferences of patients by using relevant research analytics which in turn will help make informed decisions beneficial to the needs of the patients.
| ATTRIBUTES | DETAILS |
| STUDY PERIOD | 2023-2033 |
| BASE YEAR | 2023 |
| FORECAST PERIOD | 2024-2033 |
| HISTORICAL PERIOD | 2023-2024 |
| UNIT | VALUE (USD BILLION) |
| KEY COMPANIES PROFILED | AbbVie Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Roche Holding AG, Janssen Pharmaceuticals Inc., Merck & Co. Inc., AstraZeneca PLC, Lupin Pharmaceuticals Inc. |
| SEGMENTS COVERED |
By Drug Type - Antihistamines, Corticosteroids, Biologics, Immunosuppressants, Others
By Route of Administration - Oral, Injectable, Topical
By End User - Hospitals, Clinics, Homecare Settings, Pharmacies
By Geography - North America, Europe, APAC, Middle East Asia & Rest of World. |
Urticaria Drugs Market Dynamics
The Urticaria Drugs Market is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.
Market Drivers
- Technological Advancements
- Increasing Consumer Demand
- Regulatory Support
- Globalization
Market Restraints
- High Operational Costs
- Regulatory Challenges
- Market Saturation
Market Opportunities
- Emerging Markets
- Product Innovation
- Strategic Partnerships
Market Challenges
- Technological Disruptions
- Supply Chain Issues
- Changing Consumer Preferences
Urticaria Drugs Market Segmentations
Market Breakup by Drug Type
- Overview
- Antihistamines
- Corticosteroids
- Biologics
- Immunosuppressants
- Others
Market Breakup by Route of Administration
- Overview
- Oral
- Injectable
- Topical
Market Breakup by End User
- Overview
- Hospitals
- Clinics
- Homecare Settings
- Pharmacies
Market Breakup by Region
North America
- United States of America
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Players in the Urticaria Drugs Market
This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.
- AbbVie Inc.
- Novartis AG
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Regeneron Pharmaceuticals Inc.
- Roche Holding AG
- Janssen Pharmaceuticals Inc.
- Merck & Co. Inc.
- AstraZeneca PLC
- Lupin Pharmaceuticals Inc.
Customization Options
Verified Industry Insights offers one of the following report customization options to our respectable clients :
Company Profiling
● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)
Competitive Benchmarking
● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research
Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439
© 2024 Verified Industry Insights. All Rights Reserved